Matthew Zirwas

Featured in: Favicon

wiley.com

jamanetwork.com Favicon

dovepress.com Favicon

healio.com Favicon

hcplive.com Favicon

unirioja.es Favicon

mdedge.com Favicon

jaad.org

dermatologytimes.com Favicon

practicaldermatology.com + 4 more

Articles

Understand Effective Strategies for Monitoring Topical Dermatological Agents

1 month ago | pharmacytimes.com | Aislinn Antrim |Matthew Zirwas

CommentaryVideoMarch 18, 2025Author(s):,Matthew Zirwas, MD, highlights the discrepancy between perceived and actual usage, citing studies that reveal patients often overestimate their compliance. In an interview with Pharmacy Times, Matthew Zirwas, MD, discusses the challenges of monitoring medication adherence, particularly with topical treatments such as ruxolitinib (Opzelura; Incyte).
Pharmacists Are Crucial Team Members When Managing Affordability, Access to Opzelura

1 month ago | pharmacytimes.com | Aislinn Antrim |Matthew Zirwas

CommentaryArticleMarch 14, 2025Author(s):,Matthew Zirwas, MD, addresses the significant financial burden associated with the medication, emphasizing the importance of pharmacists in navigating prior authorizations and access patient support programs. In an interview with Pharmacy Times, Matthew Zirwas, MD, discusses the challenges and benefits of using ruxolitinib (Opzelura; Incyte) for atopic dermatitis and vitiligo.
Educating Patients About Adverse Effects Can Improve Adherence

1 month ago | pharmacytimes.com | Aislinn Antrim |Matthew Zirwas

CommentaryVideoMarch 11, 2025Author(s):,Patients may have concerns about the boxed warning and other potential adverse effects associated with topical ruxolitinib for atopic dermatitis and vitiligo. In this interview with Pharmacy Times, Matthew Zirwas, MD, discusses common misconceptions and adherence challenges surrounding topical ruxolitinib (Opzelura; Incyte Dermatology) in vitiligo and atopic dermatitis.
Celebrating Advancements in AD With Topical Creams

Jan 13, 2025 | dermatologytimes.com | Matthew Zirwas

2 Commerce Drive Cranbury, NJ 08512
State-of-the-State Update: Chronic Hand Eczema

Jan 10, 2025 | dermatologytimes.com | Matthew Zirwas

I’ve been a patch tester for the past 20 years and authored one of the few textbook chapters on chronic hand eczema (CHE) (Fisher’s Contact Dermatitis, 7th edition), so the condition has been near and dear to my heart for a long time. The reason there isn’t a ton about CHE in literature is that it is extremely difficult to sort out the etiology in any given patient outside seeing their response to therapy. If they improve after avoiding irritants, it’s irritant contact dermatitis (ICD).
Test Your Knowledge: Chronic Hand Eczema

Nov 1, 2024 | dermatologytimes.com | Matthew Zirwas

Chronic Hand Eczema (CHE) is a heterogeneous, long-lasting inflammatory skin disease with varying clinical presentations, complicating diagnosis and management. The condition can significantly impact quality of life, with visible symptoms leading to psychosocial and socioeconomic burdens. Use the quiz below to test your knowledge on a few pearls of the condition. What is the Hand Eczema Severity Index (HECSI) most similar to? EASI SCORAD POEM DLQI“I know what you're thinking, chronic hand eczema?
Clinical Insights Into Challenging Atopic Dermatitis Cases: Part 1

Jul 8, 2024 | dermatologytimes.com | Matthew Zirwas

In a series of Dermatology Times Case-Based Roundtable® events, leading dermatologists and their local peers tackled some of the most challenging cases of atopic dermatitis (AD). These gatherings provided an invaluable platform for collaborative discussion, innovative problem-solving, and the exchange of cutting-edge treatment strategies.
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis

May 3, 2023 | jamanetwork.com | Matthew Zirwas |Zoe D. Draelos |Janet Dubois |Leon Kircik

Key PointsQuestion What is the efficacy and safety of once-daily roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis? Findings In this randomized clinical trial that included 226 patients with seborrheic dermatitis, 73.8% of roflumilast-treated patients achieved Investigator Global Assessment success at week 8 compared with 40.9% in the vehicle group, a statistically significant difference.